

Hong Kong Exchanges and Clearing Limited and the Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



偉倫生物科技有限公司
Wai Chun Bio-Technology Limited

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 660)

**DELAY IN PUBLICATION OF THE AUDITED RESULTS
FOR THE YEAR ENDED 31 DECEMBER 2020**

This announcement is made by the board (the “**Board**”) of directors of Wai Chun Bio-Technology Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the provisions of inside information under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the laws of Hong Kong).

Due to the impact of COVID-19 and subject to travel restrictions and quarantine policies imposed by the Chinese government, ZHONGHUI ANDA CPA Limited (the “**Auditor**”), the new auditor of the Company appointed on 25 February 2021, requires additional time to carry out certain audit procedures and necessary field work in the PRC. In particular, there has been a delay in commencing the audit work for deploying the staff to go to China for 7 days and above. It also takes extra time for the Auditor to prepare and complete its work such as audit work done on the opening balances, the stock rollback exercise, the impairment of assets including receivables, and also waiting for the return of audit confirmations etc.. Accordingly, it was unable to complete the audit for the Company to release the Group’s annual results for the year ended 31 December 2020 (the “**Annual Results**”) by 31 March 2021 in accordance with the requirements of the Listing Rules.

Based on the information available to the Board, it is expected that the audited Annual Results will be available for publication by 30 April 2021. Accordingly, the Board meeting to approve the Annual Results will be postponed and the Company will make further announcement in accordance with the Listing Rules in due course.

By Order of the Board
Wai Chun Bio-Technology Limited
LAM Ching Kui
Chairman and Chief Executive Officer

Hong Kong, 31 March 2021

As at the date of this announcement, the Board comprises:

Executive Director:

LAM Ching Kui (*Chairman and Chief Executive Officer*)

Independent Non-executive Directors:

CHAN Cheuk Ho

WAN Bo

HAU Pak Man